Rapid Diagnostics Sector Set to Surpass $26.4 Billion by 2029
Meticulous
Research®—a leading global market research company published a research report
titled “Rapid Diagnostics Market by Product (Kits [OTC, Professional], Readers),
Platform (Lateral Flow, Serological, PCR), Application (Blood Glucose,
Infectious Diseases, Pregnancy, Drugs of Abuse), End User (Hospitals,
Diagnostic Labs, Home Care) — Global Forecasts to 2029.”
Download Free Sample Report@ https://www.meticulousresearch.com/download-sample-report/cp_id=5240?utm_source=blog&utm_medium=social&utm_campaign=product&utm_content=20-11-2024
According to
the latest report from Meticulous Research®, the global rapid diagnostics
market is projected to grow at a CAGR of 1.4% from 2022 to 2029, reaching
$26.40 billion by 2029. The growth is driven by the increasing demand for
point-of-care diagnostics, a rising prevalence of chronic diseases along with
an aging population, the need for rapid decision-making in emergency settings,
and advancements in technology. However, inconsistencies in test results are
anticipated to limit market growth.
The market is
segmented by product (kits and test readers/analyzers), platform (immunoassays,
molecular detection, and other platforms), application (blood glucose testing,
cardiac metabolism testing, infectious disease testing, coagulation testing,
pregnancy & fertility testing, fecal occult testing, hematology testing,
tumor/cancer markers testing, drug abuse testing, urinalysis, and cholesterol
testing), end user (hospitals & clinics, diagnostic laboratories, home
care/self-testing, and other end users), and geography. The report also
assesses key industry players and their market shares globally and regionally.
Product
Segment: In 2022, the kits segment is
expected to hold the largest market share due to their growing adoption and
repeated use. The expansion of disease-specific kits for early chronic disease
diagnosis and ongoing technological advancements are key factors contributing
to this segment's dominance.
Platform
Segment: The immunoassays segment is
anticipated to lead the market in 2022, driven by the ability of immunoassay
kits to deliver fast, accurate results with high sensitivity in point-of-care
diagnostics. The COVID-19 pandemic has accelerated the development of sensitive
and accurate immunoassay kits. For instance, Stream Bio (U.K.) and Chelsea
Technologies (U.K.) launched Brightline Diagnostics (DX) in May 2021, creating
the Claritas platform which combines fluorescent lateral flow tests with a sensitive
handheld reader, offering significant advantages over existing assays.
Application
Segment: Infectious disease testing is
expected to account for the largest market share in 2022 due to the increasing
incidence of infectious diseases and the demand for affordable testing in
emerging markets. For example, the U.S. saw a significant rise in hepatitis A
virus (HAV) infections from 2014 to 2019, and China has a high prevalence of
infectious diseases, including HIV.
End User
Segment: Hospitals & clinics are
projected to dominate the market in 2022, driven by the rising demand for
point-of-care diagnostics and increased healthcare spending. For instance,
India’s hospital and healthcare sector is experiencing rapid growth, with the
government planning to invest over $200 billion in medical infrastructure by
2024.
The report
provides a comprehensive analysis of major regions, including North America
(U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and the Rest of
Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific),
Latin America, and the Middle East & Africa.
Key
Players: Leading companies in the global
rapid diagnostics market include Abbott Laboratories (U.S.), Becton, Dickinson
and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche
Ltd. (Switzerland), ACON Laboratories, Inc. (U.S.), Creative Diagnostics
(U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.),
BioMérieux S.A. (France), Alfa Scientific Designs, Inc. (U.S.), BTNX Inc.
(Canada), Meridian Bioscience, Inc. (U.S.), and Trinity Biotech plc (Ireland).
About Meticulous
Research®:
We
are a trusted research partner for leading businesses worldwide, empowering
Fortune 500 organizations and emerging enterprises with actionable market
intelligence tailored to drive revenue transformation and strategic growth. Our
insights reveal forward-looking revenue opportunities, providing our clients
with a competitive edge through a diverse suite of research
solutions—syndicated reports, custom research, and direct analyst engagement.
Each
year, we conduct over 300 syndicated studies and manage 60+ consulting
engagements across eight key industry sectors and 20+ geographic markets. With
a focus on solving the complex challenges facing global business leaders, our
research enables informed decision-making that propels sustainable growth and
operational excellence. We are dedicated to delivering high-impact solutions
that transform business performance and fuel innovation in the competitive
global marketplace.
Contact
Us:
Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
Email- sales@meticulousresearch.com
USA: +1-646-781-8004
Europe: +44-203-868-8738
APAC: +91 744-7780008
Visit Our Website: https://www.meticulousresearch.com/
For Latest Update Follow Us:
LinkedIn- https://www.linkedin.com/company/meticulous-research
Meticulous Blog | Top Market Research Reports Blog - https://meticulousblog.org/
Comments
Post a Comment